Persistent Corneal Epithelial Defect (PCED) Market Outlook

Thelansis’s “Persistent Corneal Epithelial Defect (PCED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Persistent Corneal Epithelial Defect treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Persistent Corneal Epithelial Defect (PCED) Overview

Persistent corneal epithelial defect (PCED) is a serious ophthalmological condition defined by failure of the corneal epithelium to heal within two weeks despite conventional management, resulting from a pathological disruption of the normal epithelial regenerative cycle — dependent on limbal stem cell integrity, neurotrophic support, adequate tear film, and stromal substrate health. Underlying aetiologies are diverse, encompassing neurotrophic keratopathy — from herpetic, diabetic, or surgical nerve damage — ocular surface disease, limbal stem cell deficiency, chemical or thermal injury, iatrogenic medication toxicity, and systemic conditions including Sjögren syndrome and graft-versus-host disease. Patients present with persistent epithelial breakdown, pain or paradoxical hypoaesthesia in neurotrophic cases, photophobia, and progressive visual compromise, with risk of stromal melting, ulceration, perforation, and permanent scarring. Diagnosis is clinical — slit-lamp biomicroscopy with fluorescein staining — supplemented by corneal sensitivity assessment and anterior segment OCT. Management addresses the underlying aetiology alongside epithelial healing promotion; preservative-free lubrication, bandage contact lenses, and autologous or allogeneic serum eye drops provide supportive scaffolding. Cenegermin — recombinant human nerve growth factor — represents a landmark approved therapy specifically targeting neurotrophic keratopathy-associated PCED, promoting epithelial regeneration through neurotrophin-mediated mechanisms. Surgical options including amniotic membrane transplantation, tarsorrhaphy, and conjunctival flap are reserved for refractory cases. Prognosis depends on aetiology and chronicity; early specialist intervention, meticulous ocular surface optimisation, and patient-centred monitoring are indispensable to preserving corneal integrity and visual function.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)